In the beginning of March Pfizer reported that the company had identified certain antiviral compounds it had in development that have the potential to inhibit coronaviruses and is engaging with a third party to screen the compounds.
The company said it hopes to have the results from that screening by the end of March and if any of the compounds are successful, it would hope start testing them by the end of the year.
“We believe that the best way to advance the development of treatments and vaccins against covid-19 is to gather resources and knowledge from the entire pharmaceutical industry,” says Mikael Dolsten, Chief Scientific Officer, Pfizer.
